Association Between RVT and Prognosis After Neoadjuvant Targeted Therapy in EGFR NSCLC
Recruiting
Observational Study
Lung Cancer (NSCLC)
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 – 80
- Sex
- Any
- Study type
- Observational
- Participants needed
- 120 (estimated)
- Sponsor
- Guangdong Provincial People's Hospital · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
EGFR-mutated NSCLC is a distinct subtype that responds well to targeted therapies. Neoadjuvant targeted therapy aims to downstage tumors and improve surgical outcomes, but the prognostic role of residual viable tumor (RVT) remains unclear. This retrospective study examines the association between RVT and survival outcomes. The findings will further validate the importance of RVT as a surrogate.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Age 18-80 years old;
* Pathologically diagnosed EGFR-mutated non-small cell lung cancer (NSCLC);
* Treated with neoadjuvant targeted therapy;
* Undergoing definitive surgery.
Exclusion Criteria:
* A history of prior chemotherapy, immunotherapy, or radiotherapy.
* A history o…
Contacts